This Is MS Multiple Sclerosis Knowledge & Support Community

Harry, I can't believe my eyes when I read your messages. 8O I agree and if anyone else on this forum would have posted that message in the interest of the patient I would not have said a word. But that message by Better, in my opinion, had nothing to do with patient interest but potential self prof...

. New MS drug on licensing fast track Daily Post (Liverpool) - Aug. 31, 2006 A NEW drug to treat multiple sclerosis has been accepted for a fast-track assessment process by the Government's health watchdog. The National Institute for Health and Clinical Excellence (Nice) is assessing Natalizumab, ma...

From another message board Financial Assistance for MS Patients Here is some information for MS patients on getting financial assistance with the expense of Tysabri, and for those who want to make a tax deductible donation to assist MS patients. For MS patients, you must first qualify for Tysabri an...

Interesting info from an other messageboard. MS ActiveSource and MS Patients For Choice In the next week or so, people can call MS ActiveSource at 1-800-456-2255, give them a ZIP Code, and they will be able to provide contact information for a couple of nearby TOUCH-enrolled neurologists and infusio...

Sharon



Thanks for your post.

Better--You wrote

The article is not from me but from Ken Kam / Marketocracy

Best regards

Harry, Personally, I don't think MS pays much if any attention to these drugs and does what it wants and when it wants to. Then how do you explain this post from today from another message board ? " Just called the Metro Infusion Center near my home; one of 10 MIC offices in the Chicago market....

. Ken Kam on Tysabri, Elan Teva & Serono We are issuing this alert because Élan Corporation, plc ADR (nyse: ELN) fell 5.4% last Friday when two competitors, Teva Pharmaceutical Industries Ltd. (nasdaq: TEVA) and Serono SA (nyse: SRA), joined forces and uncorked another shot below the belt. In ou...

. TYSABRI® Pricing TYSABRI® (natalizumab) will be available upon the completion of key activities related to the risk management plan, including finalization of educational and training materials, internal validation of systems based on final FDA requirements and training of internal personnel. As s...

From NCB Equity Research Morning News & Views Tysabri Conference Call Highlights • To clarify some confusion in the market, BiogenIdec stated on the joint CC with Elan that there was nothing in the label that precludes first-line use of Tysabri. When the prescriber and patient agree, the label a...

.
Very interesting article.

MULTIPLE SCLEROSIS PATIENTS
V. FDA OVERCAUTION

by Lauren Roberts

http://www.wlf.org/upload/051906robertsLOL.pdf
.

. Patient Power - The FDA Doesn't Have to Decide Everything By John E. Calfee Posted: Monday, May 1, 2006 ARTICLES The Weekly Standard (Washington) Publication Date: May 8, 2006 Thousands of multiple sclerosis (MS) patients got an all-too-familiar message recently: Their lives are ruled by experts. ...

From IndyStar.com April 18, 2006 News and notes Multiple sclerosis patients surveyed on drug Tysabri A survey of 200 patients in West Palm Beach, Fla., with a type of multiple sclerosis known as relapsing remitting has found that more than half would definitely or probably use a drug that significan...

6 April 2006 New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis SAN DIEGO--(BUSINESS WIRE)--April 6, 2006-- Data presented at American Academy of Neurology Annual Meeting also Show Impact on Measures of Visual Functio...

.
Risk Control Plan Key To Natalizumab's Return

ELIZABETH MECHCATIE (Senior Writer)

http://www.clinicalneurologynews.com/ar ... 4/fulltext
.

29 March 2006 Biogen Idec and Elan Announce Re-Initiation of TYSABRI® Clinical Trial Dosing in Multiple Sclerosis CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--March 29, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that they have enrolled and dosed...